EBOS Group Limited/Announcement
EBOS Group Limited logo

ASX Appendix 3Y

Capital Change9 September 2025EBOHealthcare

Appendix 3Y
Change of Director’s Interest Notice




+ See chapter 19 for defined terms.


01/01/2011 Appendix 3Y Page 1


Rule 3.19A.2

Appendix 3Y


Change of Director’s Interest Notice


Information or documents not available now must be given to ASX as soon as available. Information and

documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11


Name of entity EBOS Group Limited

ABN N/A


We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for

the director for the purposes of section 205G of the Corporations Act.


Name of Director

Matthew Musico

Date of last notice

3 January 2025


Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust


Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should

be disclosed in this part.


Direct or indirect interest

Direct

Nature of indirect interest

(including registered holder)

Note: Provide details of the circumstances giving rise to the relevant

interest.


N/A

Date of change

4 September 2025

No. of securities held prior to change

33,687 performance rights. The performance

rights were issued during the course of

Mr Muscio’s employment as CEO, EBOS

Medical Technology.

Class

Performance rights

Number acquired

N/A

Number disposed

15,828 performance rights (lapsed)

Value/Consideration

Note: If consideration is non-cash, provide details and estimated

valuation



No. of securities held after change

17,859 performance rights

Appendix 3Y
Change of Director’s Interest Notice




+ See chapter 19 for defined terms.


Appendix 3Y Page 2 01/01/2011


Nature of change

Example: on-market trade, off-market trade, exercise of options,

issue of securities under dividend reinvestment plan, participation in

buy-back

Lapse of performance rights in accordance

with their terms of issue.


Part 2 – Change of director’s interests in contracts


Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should

be disclosed in this part.



Detail of contract


Nature of interest




Name of registered holder

(if issued securities)



Date of change


No. and class of securities to which

interest related prior to change

Note: Details are only required for a contract in

relation to which the interest has changed



Interest acquired


Interest disposed


Value/Consideration

Note: If consideration is non-cash, provide details

and an estimated valuation



Interest after change



Part 3 –

+

Closed period


Were the interests in the securities or contracts detailed

above traded during a

+

closed period where prior written

clearance was required?

No.

If so, was prior written clearance provided to allow the trade

to proceed during this period?

N/A

If prior written clearance was provided, on what date was this

provided?

N/A

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.

Other issuers discussed similar conditions around this time

Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.